WO2000016777A1 - Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas - Google Patents
Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas Download PDFInfo
- Publication number
- WO2000016777A1 WO2000016777A1 PCT/IB1999/001503 IB9901503W WO0016777A1 WO 2000016777 A1 WO2000016777 A1 WO 2000016777A1 IB 9901503 W IB9901503 W IB 9901503W WO 0016777 A1 WO0016777 A1 WO 0016777A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- mammal
- treating
- receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention is directed to the use of certain pyrido[1,2-a]-pyrazine derivatives, also described as bis-azabicyciic compounds, in the treatment of Parkinson's disease, attention deficit hyperactivity disorder ("ADHD") and microadenomas in mammals, including humans. It is also directed to the use of a dopamine-2 (D2) receptor agonist in combination with a serotonin-1A (5HT 1A ) receptor agonist for the treatment for Parkinson's Disease. It is also directed to the use of an alpha-2 ( ⁇ 2 ) adrenergic receptor ligand in combination with either a D2 receptor agonist or a 5HT 1A receptor agonist for the treatment of ADHD.
- D2 dopamine-2
- 5HT 1A serotonin-1A
- D2 receptor agonist in combination with a 5HT ⁇ A receptor agonist for the treatment of ADHD. It is also directed to the use of an alpha-2 ( ⁇ 2 ) adrenergic receptor ligand in combination with both a D2 receptor agonist and a 5HT 1A receptor agonist for the treatment of ADHD.
- Serotonin plays a role in several psychiatric disorders, including anxiety, Alzheimer's disease, depression, nausea and vomiting, eating disorders, and migraine. (See Rasmussen et aL, "Chapter 1. Recent Progress in Serotonin (5HT) ⁇ A Receptor Modulators", in Annual
- Serotonin also plays a role in both the positive and negative symptoms of schizophrenia. (See Sharma et a]., Psychiatric Annals.. 26 (2), February, 1996, pp. 88-92.) Serotonin 1A receptor agonists have been shown to increase prefrontal cortex dopamine (DA) release. See Wedzony et a]., Eur. J. Pharmacol.. 305: 73-78 (1996).
- Buspirone a 5HT 1A receptor agonist
- Buspirone a 5HT 1A receptor agonist
- Serotonin 1A receptor agonists have also been shown to reverse neuroleptic induced dystonia in nonhuman primates, a condition that mimics symptoms of human Parkinson's disease. See Casey, D. E., Neuropsvchopharmacol..
- Symptoms associated with ADHD have been shown to be relieved by catecholamine releasing drugs such as methylphenidate, and by postsynaptic ⁇ 2 adrenergic receptor agonists such as clonidine. Also, presynaptic ⁇ 2 adrenergic receptor antagonists have been shown to increase norepinephrine (NE) release.
- catecholamine releasing drugs such as methylphenidate
- postsynaptic ⁇ 2 adrenergic receptor agonists such as clonidine
- presynaptic ⁇ 2 adrenergic receptor antagonists have been shown to increase norepinephrine (NE) release.
- a number of 1-(2-pyrimidinyl)-4-[4-(cyclic-imido)butyl]piperidine derivatives have been disclosed as anxiolytic agents which are generally lacking sedative activity.
- buspirone where the cyclic-imido group is 4,4-tetramethylene-piperidine-2,6-dion-1-yl (Wu et aL, United States Patents 3.717,634 and 3,907,801); Casten et aL, United States Patent 4,182,763); gepirone, where the group is 4,4-dimethylpiperidine-2,6-dion-1-yl (Temple, Jr., United States Patent 4,423,049); and ipsapirone, where the group is 1 ,1-dioxobenzo[d] isothiazol-3(2H)-on-yl (Dompert et aL, German patent publication 3,321,969-A1).
- This invention relates to a method of treating a disorder selected from Parkinson's disease, ADHD, and microadenomas in a mammal, including a human, comprising administering to a mammal in need of such treatment an amount of a compound of the formula
- X is N or CH
- SCH 2 OCH 2 , Y 1 (CH 2 ) n or Y 1 (CH ) n substituted on carbon with up to 2 methyl groups; n is 1 or 2;
- Y 1 is CH 2 , NH or NCH 3 ; that is effective in treating such disorder.
- Y is preferably
- a particularly preferred compound is that wherein Z is Y 1 (CH 2 ) n , Y 1 is CH 2 , n is 1 and
- X is N.
- the compounds of formula I are D2 receptor agonists and useful in the treatment of Parkinson's disease. They also exhibit 5HT 1A receptor agonist activity.
- the compounds of formula I also exhibit activity as ⁇ 2 adrenergic receptor antagonists and are useful in treatment of ADHD.
- the compounds increase hippocampal NE release and also increase prefrontal cortex DA release.
- the compounds of the formula I that are basic can form acid addition salts with a variety of organic and inorganic acids.
- the acids that can be used to prepare the pharmaceutically acceptable acid addition salts of the aforementioned base compounds of the formula I are those which form non-toxic acid addition salts, Le., salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, acetate, lactate, citrate, acid citrate, tartrate, bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate, ethanesuifonate, benzenesulfonate, p-toluenesulfonate and pamoate [Le., 1,1'-methylene-bis-(2-hydroxy-3- naphthoate)]salts.
- treating refers to reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition.
- treatment refers to the act of treating, as “treating” is defined immediately above. - -
- This invention also relates to a method for treating Parkinson's Disease in a mammal, including a human, comprising administering to a mammal in need of such treatment a D2 receptor agonizing agent in combination with a 5HT 1A receptor agonizing agent, wherein the two foregoing active agents are present in amounts such that the combination of such agents is effective in treating Parkinson's Disease.
- This invention also relates to a pharmaceutical composition for treating Parkinson's disease in a mammal, including a human, comprising: (a) a D2 receptor agonizing agent or a pharmaceutically acceptable salt thereof; (b) a 5HT 1A receptor agonizing agent or pharmaceutically acceptable salt thereof; and (c) a pharmaceutically acceptable carrier; wherein the foregoing two active agents are in the composition in amounts such that the combination of such agents is effective in treating Parkinson's disease.
- This invention also relates to a method of treating ADHD in a mammal, including a human, comprising administering to a mammal in need of such treatment an ⁇ 2 adrenergic receptor ligand, or pharmaceutically acceptable salt thereof, in combination with either a D2 receptor agonizing agent or a 5HT 1A receptor agonizing agent, or pharmaceutically acceptable salt thereof, wherein the foregoing two active agents are present in amounts such that the combination of such active agents is effective in treating ADHD.
- This invention also relates to a pharmaceutical composition for treating ADHD in a mammal, including a human, comprising: (a) an ⁇ 2 adrenergic receptor ligand or a pharmaceutically acceptable salt thereof; (b) a D2 receptor agonizing agent or a 5HT 1A receptor agonizing agent, or a pharmaceutically acceptable salt thereof; and (c) a pharmaceutically acceptable carrier; wherein the two foregoing active agents are present in the composition in amounts such that the combination of such agents is effective in treating ADHD.
- This invention also relates to a method of treating ADHD in a mammal, including a human, comprising administering to a mammal in need of such treatment a D2 receptor agonizing agent, or pharmaceutically acceptable salt thereof, in combination with a 5HT 1A receptor agonizing agent, or pharmaceutically acceptable salt thereof, wherein the foregoing two active agents are present in amounts such that the combination of such active agents is effective in treating ADHD.
- This invention also relates to a pharmaceutical composition for treating ADHD in a mammal, including a human, comprising: (a) a D2 receptor agonizing agent or a pharmaceutically acceptable salt thereof; (b) a 5HT 1A receptor agonizing agent or a pharmaceutically acceptable salt thereof; and (c) a pharmaceutically acceptable carrier; wherein the two foregoing active agents are present in the composition in amounts such that the combination of such agents is effective in treating ADHD.
- This invention also relates to a method of treating ADHD in a mammal, including a human, comprising administering to a mammal in need of such treatment an ⁇ 2 adrenergic receptor ligand, or pharmaceutically acceptable salt thereof, in combination with a D2 receptor agonizing agent, or pharmaceutically acceptable salt thereof, and also a 5HT 1A receptor agonizing agent, or pharmaceutically acceptable salt thereof, wherein the three foregoing active agents are present in amounts such that the combination of such active agents is effective in treating ADHD.
- This invention also relates to a pharmaceutical composition for treating ADHD in a mammal, including a human, comprising: (a) an ⁇ 2 adrenergic receptor ligand or a pharmaceutically acceptable salt thereof; (b) a D2 receptor agonizing agent or a pharmaceutically acceptable salt thereof; (c) a 5HT 1A receptor agonizing agent or a pharmaceutically acceptable salt thereof; and (d) a pharmaceutically acceptable carrier; wherein the foregoing three active agents are present in the composition in amounts such that the combination of such agents is effective in treating ADHD.
- Compounds of the formula I may contain chiral centers and therefore may exist in different enantiomeric and diastereomic forms.
- the term "compounds of the formula I", as used herein, refers to all optical isomers and all other stereoisomers of compounds of the formula I, as defined above, and to all racemic and other mixtures thereof, and to all pharmaceutical compositions and methods of treatment defined above that contain or employ such isomers or mixtures.
- Formula I above includes compounds identical to those depicted but for the fact that one or more hydrogen or carbon atoms are replaced by isotopes thereof. Such compounds are useful as research and diagnostic tools in metabolism pharmacokinetic studies and in binding assays. Specific applications in research include radioligand binding assays, autoradiography studies and in yj o binding studies.
- D2 receptor agonizing agents examples include, but are not limited to, compounds of the formula I and the pharmaceutically acceptable salts, pergolide, bromocriptane, ropinerol, and pramipexole.
- 5HT 1A receptor agonizing agents examples include, but are not limited to: (a) compounds of the formula I and their pharmaceutically acceptable salts, (b) buspirone (U.S. Patents 3,717,638; 3,907,801 and 4,182,763); (c) gepirone (U.S. Patent 4,423,049); (c) ipsapirone (German patent publication 3,321 ,969-A1 ); and (d) and flexinoxan.
- ⁇ 2 adrenergic receptor antagonizing agents examples include, but are not limited to, compounds of the formula I and their pharmaceutically acceptable salts, yohimbine and idazoxan.
- Examples of more specific embodiments of this invention are the above methods of treating ADHD and pharmaceutical compositions for the treatment of ADHD that employ an ⁇ 2 adrenergic receptor ligand wherein such ligand is a presynaptic ⁇ 2 adrenergic receptor antagonist or a post synaptic ⁇ 2 adrenergic receptor agonist.
- a preferred method of this invention is a method of treating Parkinson's Disease in a mammal, including a human, comprising administering to a mammal in need of such treatment an amount of the following compound of the formula I shown below:
- “sunipetron” or pharmaceutically acceptable salt thereof, that is effective in treating Parkinson's Disease.
- Another preferred embodiment of this invention is a method for treating ADHD in a mammal including a human, comprising administering to a mammal in need of such treatment an amount of sunipetron, or pharmaceutically acceptable salt thereof, that is effective in treating ADHD.
- Another preferred method of this invention is a method for treating microadenomas in a mammal including a human, comprising administering to a mammal in need of such treatment an amount of sunipetron, or pharmaceutically acceptable salt thereof, that is effective in treating microadenomas.
- Figure 1 shows parkinsonian scores obtained in monkeys treated with either 0.5 mg/kg or .0 mg/kg of a compound of formula I.
- the compounds of the formula I are capable of forming a wide variety of different salts with various inorganic and organic acids.
- the acids that can be used to prepare the pharmaceutically acceptable acid addition salts of the base compounds of this invention are those which form non-toxic acid addition salts, Le., salts containing pharmacologically acceptable anions, such as hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate or bisulfate, phosphate or acid phosphate, acetate, lactate, citrate or acid citrate, tartrate or bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate and pamoate [Le., 1,1'- methylene-bis-(2-hydroxy-3-naphthoate)] salts.
- salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate a compound of the formula I from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent, and subsequently convert the free base to a pharmaceutically acceptable acid addition salt.
- the acid addition salts of the base compounds of this invention are readily prepared by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is obtained.
- a compound of the formula I, or a pharmaceutically-acceptable salt thereof is administered in an amount of about 2-300 mg/day, in single or divided daily doses. In particular cases, dosages outside that range are prescribed at the discretion of the attending physician.
- the preferred route of administration is generally oral, but parenteral administration (e.g., intramuscular, intravenous, intrademal) will be preferred in special cases, j., where oral absorption is impaired as by disease, or the patient is unable to swallow.
- the compound of formula I is administered in an individual dosage of about 1.0 mg/kg at a frequency of about three times per day.
- a controlled-release formulation can be employed instead that is administered once per day.
- the compound is administered in an amount required by the particular route of administration to achieve a plasma concentration of between 100 and 500 ng/ml, preferably about 200 ng/ml, at between 2 and 3 hours following administration.
- compositions comprising at least one of the compounds of the formula (I), or a salt thereof, together with a pharmaceutically acceptable vehicle or diluent.
- Such compositions are generally formulated in a conventional manner utilizing solid or liquid vehicles or diluents as appropriate to the mode of desired administration: for oral administration, in the form of tablets, hard or soft gelatin capsules, suspension, granules, powders and the like; and, for parenteral administration, in the form of injectable solutions or suspensions, and the like.
- Binding of a compound to the D2 receptor can be determined using the follow D2 receptor binding assay.
- LTr cells expressing the human D 2 long (D 2 _) receptor are grown (T-175 flasks) in D- glucose containing minimal essential media (DMEM, Gibco) supplemented with 10% fetal bovine serum (FBS).
- DMEM D- glucose containing minimal essential media
- FBS fetal bovine serum
- the cells are dislodged with 5 mM EDTA in PBS and homogenized in 50 mM Tris HCI (pH 7.4) with 5mM MgS0 4 , using a Brinkman Polytron at setting 6 for 20 sec.
- Membranes are recovered after multiple rounds of separation by centrifugation and resuspension in fresh ice-cold buffer.
- tissue ⁇ 2 mg tissue, wet weight
- incubation buffer 50 mM Tris HCI, 120 mM NaCl, 2 mM MgCI 2 , 5 mM KCI, 5 mM CaCI 2 , pH 7.2
- test drug 50 mM Tris HCI, 120 mM NaCl, 2 mM MgCI 2 , 5 mM KCI, 5 mM CaCI 2 , pH 7.2
- [ 3 H]-spiperone 0.06 nM final concentration, Amersham, Arlington Heights IL
- Non-specific binding is determined in the presence of 2 uM (+)-butaclamol.
- incubations are terminated by rapid filtration through Whatman GF/B filters using a Brandel cell harvester.
- the membranes are washed using 3 X 4 ml of ice-cold buffer and membrane-bound ligand is determined by liquid scintillation counting of the filters in Ready-Safe scintillation cocktail (for tritiated ligands).
- the Ka (0.06 nM) for the radioligand is determined previously by saturation analysis and used to calculate apparent r s by means of the Cheng-Prusoff equation.
- the agonist or antagonist activity of a compound at the D2 receptor can be determined using the following three assays.
- GH 4 C ! cells derived from rat pituitary, expressing either the long or short forms of the human D 2 receptor, are grown to confluence in (HAM) F-10 Nutrient Mixture (Gibco) supplemented with 10% FBS and 2 mM l-glutamine and 10 U/ml penicillin-streptomycin in T- 175 flasks.
- the cells are dislodged with 5 mM ethylenediamine tetraacetic acid (EDTA) in phosphate buffered saline (PBS) and resuspended in PBS containing 5 mM MgCI 2 , 30 mM hydroxyethylpiperizine-N-ethanesulfonic acid (HEPES), and 50 mM isobutyl methyl xanthine (IBMX).
- Cells ( ⁇ 200,000/tube) are exposed to 5 mM forskolin, 100 nM quinpirole or forskolin plus quinpirole plus antagonist for 11 minutes. In experiments with antagonists, cells are exposed to the antagonists 11 minutes prior to quinpirole challenge.
- the ventral tegmental area is blocked and glued using cyanoacrylate to the stage of a Lancer Vibratome (Series 1000) filled with ice cold medium.
- Coronal slices 350 ⁇
- oxygenated medium 22°C
- slices are placed on a nylon net in a recording chamber where they are completely submerged in continually flowing medium at 35°C (-1 ml/min). All drugs are applied by switching the perfusion medium to a solution containing the drug.
- Spontaneous extracellular action potentials are recorded using 0.9% saline-filled glass pipettes (6-8 MW).
- Firing rates are plotted on-line in bins of 10 or 20 seconds and alterations in firing rate are calculated using average rates over 2 min epochs before and after drug application. Concentration-response curves are constructed and analyzed by linear regression. (3) Microdialysis I shaped concentric microdialysis probes are constructed out of dialysis fiber
- the probes 9 mm long with 2 mm length of exposed dialysis membrane are implanted into the nucleus accumbens (AP 1.7 , ML -1.2 ,DV -8.0) of male Sprague Dawley rats (300-350g) anesthetized with ketamine (75 mg/kg) and xylazine (10 mg/kg).
- rats are placed ih perspex cages inside insulation boxes and the probe inlets connected via flexible PEEK tubing through a dual channel fluid swivel system to a CMA/100 microinfusion pump (CMA/Microdialysis, Acton, MA).
- CMA/Microdialysis Acton, MA
- the probe is perfused overnight with artificial cerebrospinal fluid (147 mM NaCl 2 , 2.7 mM KCI, 1.3 mM CaCI 2 , 1.0 mM MgCI 2 and 0.1 mM ascorbic acid) at 0.5 ml/min.
- Analytes are separated at 35°C over a BDS Hypersil Ci ⁇ 3 m column (150 X3 mm) by reverse phase HPLC using a 75 mM potassium phosphate mobile phase of pH 5.0, containing 0.8 mM octanesulfonate, 8% methanol, 3 mM triethylamine and delivered at a flow rate of 0.35 ml/min by an ESA 580 pump.
- Amperometric detection of dopamine is performed using a glassy carbon electrode of the DECADE detector set at 550 mV vs Ag/AgCI. Extracellular levels of dopamine are quantified by comparing peak heights with those of standards.
- the agonist and antagonist activities of a particular compound of the invention at 5- HT 1A receptors can be determined using a single saturating concentration according to the following procedure. Male Hartley guinea pigs are decapitated and 5-HT 1A receptors are dissected out of the hippocampus. The individual tissues are homogenized in 5 mM HEPES buffer containing 1 mM EGTA (pH 7.5) using a hand-held glass-Teflon® homogenizer and centrifuged at 35,000 x g for 10 minutes at 4°C.
- the pellets are resuspended in 100 mM HEPES buffer containing 1 mM EGTA (pH 7.5) to a final protein concentration of 20 mg (hippocampus) or 5 mg (substantia nigra) of protein per tube.
- the following agents are added so that the reaction mix in each tube contained 2.0 mM MgCI 2 , 0.5 mM ATP, 1.0 mM cAMP, 0.5 mM IBMX, 10 mM phosphocreatine, 0.31 mg/mL creatine phosphokinase, 100 mM GTP and 0.5-1 microcuries of [ 32 P]-ATP (30 Ci/mmol: NEG-003 - New England Nuclear).
- Incubation is initiated by the addition of tissue to siliconized microfuge tubes (in triplicate) at 30°C for 15 minutes. Each tube receives 20 mL tissue, 10 mL drug or buffer (at 10X final concentration), 10mL 32 nM agonist or buffer (at 10X final concentration), 20mL forskolin (3 mM final concentration) and 40 mL of the preceding reaction mix. Incubation is terminated by the addition of 100 mL 2% SDS, 1.3 mM cAMP, 45 mM ATP solution containing 40,000 dpm [ 3 H]-cAMP (30 Ci/mmol: NET-275 - New England Nuclear) to monitor the recovery of cAMP from the columns.
- This invention relates both to methods of treating Parkinson's disease and ADHD in which the two or three active agents employed are administered together, as part of the same pharmaceutical composition, as well as to methods in which these active agents are administered separately as part of an appropriate dose regimen designed to obtain the benefits of the combination therapy.
- the appropriate dose regimen, the amount of each dose administered, and specific intervals between doses of each active agent will depend upon the subject being treated, how well tolerated the drug is and the severity of the condition.
- the 5HT, A receptor agonist will be administered in an amount ranging from about 5 - 90 mg per day, in single or divided doses
- the 2 adrenergic receptor ligand will be administered in an amount ranging from about 1.0 - 100 mg per day, in single or divided doses, in the case of an ⁇ 2 adrenergic receptor antagonist, and in an amount ranging from about 0.1 - 100 mg per day, in single or divided doses, in the case of an ⁇ 2 adrenergic receptor agonist, in single or divided doses
- the D2 receptor agonist will be administered in an amount ranging from about 0.5 mg - 25 mg per day, in single or divided doses.
- the combination methods of this invention include methods wherein the desired combined activities are present in one compound or pharmaceutically acceptable salt.
- the pharmaceutical compositions of this invention that exhibit more than one pharmaceutical activity include those pharmaceutical compositions wherein all the desired pharmaceutical activities are present in one compound or pharmaceutically acceptable salt.
- the D2 receptor agonists, the 5HT 1A receptor agonists, and the ⁇ 2 receptor antagonists that are employed in the pharmaceutical compositions and methods of this invention are hereinafter also referred to as "therapeutic agents".
- the therapeutic agents can be administered via either the oral or parenteral route.
- Compositions containing both a D2 receptor agonist and a 5HT 1A receptor agonist, or all three of a D2 receptor agonist, a 5HT 1A receptor agonist and an ⁇ 2 adrenergic receptor antagonist will generally be administered orally or parenterally daily, in single or divided doses, so that the total amount of each active agent administered falls within the above guidelines.
- the therapeutic agents may be administered alone or in combination with pharmaceutically acceptable carriers or diluents by either of the routes previously indicated, and such administration may be carried out in single or multiple doses. More particularly, the therapeutic agents of this invention can be administered in a wide variety of different dosage forms, j ⁇ ., they may be combined with various pharmaceutically acceptable inert carriers in the form of tablets, capsules, lozenges, troches, hard candies, suppositories, aqueous suspensions, injectable solutions, elixirs, syrups, and the like. Such carriers include solid diluents or fillers, sterile aqueous media and various non-toxic organic solvents, etc. Moreover, oral pharmaceutical compositions can be suitably sweetened and/or flavored.
- the therapeutic compounds of this invention when administered separately (Le, not in the same pharmaceutical composition) are present in such dosage forms at concentration levels ranging from about 5.0% to about 70% by weight.
- tablets containing various excipients such as microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine may be employed along with various disintegrants such as starch (and preferably corn, potato or tapioca starch), alginic acid and certain complex silicates, together with granulation binders like polyvinylpyrrolidone, sucrose, gelatin and acacia.
- disintegrants such as starch (and preferably corn, potato or tapioca starch), alginic acid and certain complex silicates, together with granulation binders like polyvinylpyrrolidone, sucrose, gelatin and acacia.
- lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tabletting purposes.
- compositions of a similar type may also be employed as fillers in gelatin capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols.
- preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols.
- the active ingredient may be combined with various sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.
- solutions of a therapeutic agent in either sesame or peanut oil or in aqueous propylene glycol may be employed.
- the aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic.
- These aqueous solutions are suitable for intravenous injection purposes.
- the oily solutions are suitable for intraarticular, intramuscular and subcutaneous injection purposes.
- the preparation of all these solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art. The following example is intended only to illustrate the invention, and not to be interpreted as limiting its scope.
- parkinsonian monkeys were administered 0.5 mg/kg or 1.0 mg/kg of sunipetron and the severity of parkinsonian symptoms was rated at each of 4 time points after drug administration as compared with administration of a control solution ("Vehicle").
- Parkinsonian scores obtained from the study are shown in Figure 1. Combined with the estimates shown for plasma levels of the compound following administration, the data demonstrate that the maximum reduction in parkinsonian score was attained at plasma levels of approximately 200 ng/ml. The minimum effective plasma level was approximately 100 ng/ml.
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (20)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SK359-2001A SK3592001A3 (en) | 1998-09-21 | 1999-09-03 | Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas |
KR10-2003-7014169A KR20030088512A (en) | 1998-09-21 | 1999-09-03 | Pharmaceutical Agents for the Treatment of Parkinson's Disease, ADHD and Microadenomas |
CA002344670A CA2344670A1 (en) | 1998-09-21 | 1999-09-03 | Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas |
HU0103691A HUP0103691A3 (en) | 1998-09-21 | 1999-09-03 | Use of pyrido[1,2a]pyrazine derivatives for the treatment of parkinson's disease, adhd and microadenomas and medicaments containing them |
APAP/P/2001/002102A AP1456A (en) | 1998-09-21 | 1999-09-03 | Pharmaceutical agents for the treatment of parkinson's disease, ADHD and microadenomas. |
NZ509855A NZ509855A (en) | 1998-09-21 | 1999-09-03 | The use of pyrido[1,2-a]pyrazine derivatives for the treatment of Parkinson's disease, ADHD and microadenomas |
AU53831/99A AU760230B2 (en) | 1998-09-21 | 1999-09-03 | Pharmaceutical agents for the treatment of Parkinson's disease, ADHD and microadenomas |
KR10-2004-7006381A KR20040054752A (en) | 1998-09-21 | 1999-09-03 | Pharmaceutical Agents for the Treatment of Parkinson's Disease, ADHD and Microadenomas |
EEP200100179A EE200100179A (en) | 1998-09-21 | 1999-09-03 | Pharmaceutical agents for the treatment of Parkinson's disease, ADHD and microvascular adenomas |
JP2000573738A JP2002526448A (en) | 1998-09-21 | 1999-09-03 | Agent for treating Parkinson's disease, ADHD and microadenomas |
BR9913975-8A BR9913975A (en) | 1998-09-21 | 1999-09-03 | Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas |
EA200100204A EA200100204A1 (en) | 1998-09-21 | 1999-09-03 | PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PARKINSON'S DISEASE, GANVES AND MICROADENE |
IL16483999A IL164839A0 (en) | 1998-09-21 | 1999-09-03 | Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas |
EP99939567A EP1115402A1 (en) | 1998-09-21 | 1999-09-03 | Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas |
IL14150799A IL141507A0 (en) | 1998-09-21 | 1999-09-03 | Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas |
IS5852A IS5852A (en) | 1998-09-21 | 2001-02-20 | Medications for the treatment of Parkinson's disease ADHD and smallpox |
HR20010209A HRP20010209A2 (en) | 1998-09-21 | 2001-03-20 | Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas |
NO20011409A NO20011409L (en) | 1998-09-21 | 2001-03-20 | Pharmaceuticals for the treatment of Parkinson's disease, ADHD and microadenomas |
BG105445A BG105445A (en) | 1998-09-21 | 2001-04-13 | Phermaceutical agents for the treatment of parkinson's disease, adhd and microadenomas |
HK02101250.1A HK1039574A1 (en) | 1998-09-21 | 2002-02-21 | Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10119198P | 1998-09-21 | 1998-09-21 | |
US60/101,191 | 1998-09-21 | ||
US10386898P | 1998-10-12 | 1998-10-12 | |
US60/103,868 | 1998-10-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000016777A1 true WO2000016777A1 (en) | 2000-03-30 |
Family
ID=26798000
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB1999/001503 WO2000016777A1 (en) | 1998-09-21 | 1999-09-03 | Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas |
Country Status (38)
Country | Link |
---|---|
US (2) | US6300329B1 (en) |
EP (1) | EP1115402A1 (en) |
JP (1) | JP2002526448A (en) |
KR (3) | KR20030088512A (en) |
CN (1) | CN1319013A (en) |
AP (1) | AP1456A (en) |
AR (1) | AR029739A1 (en) |
AU (1) | AU760230B2 (en) |
BG (1) | BG105445A (en) |
BR (1) | BR9913975A (en) |
CA (1) | CA2344670A1 (en) |
CO (1) | CO5140075A1 (en) |
CZ (1) | CZ20011006A3 (en) |
DZ (1) | DZ2894A1 (en) |
EA (2) | EA200301063A1 (en) |
EE (1) | EE200100179A (en) |
GE (1) | GEP20033081B (en) |
GT (1) | GT199900154A (en) |
HN (1) | HN1999000146A (en) |
HR (1) | HRP20010209A2 (en) |
HU (1) | HUP0103691A3 (en) |
ID (1) | ID28028A (en) |
IL (2) | IL141507A0 (en) |
IS (1) | IS5852A (en) |
MA (1) | MA26690A1 (en) |
MY (1) | MY127939A (en) |
NO (1) | NO20011409L (en) |
NZ (1) | NZ509855A (en) |
OA (1) | OA11653A (en) |
PA (1) | PA8482001A1 (en) |
PE (1) | PE20001084A1 (en) |
PL (1) | PL346904A1 (en) |
SK (1) | SK3592001A3 (en) |
TN (1) | TNSN99177A1 (en) |
TR (2) | TR200402083T2 (en) |
TW (1) | TW518225B (en) |
WO (1) | WO2000016777A1 (en) |
YU (1) | YU21701A (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002036107A2 (en) * | 2000-11-03 | 2002-05-10 | Motac Neuroscience Limited | Treatment of motor fluctuations with 5-hydroxytryptamine 1a receptor activity enhancing coumpounds |
WO2002102988A2 (en) * | 2001-06-18 | 2002-12-27 | Psychiatric Genomics, Inc. | Method for neural stem cell differentiation using 5ht-1a agonists |
WO2008083442A1 (en) * | 2007-01-10 | 2008-07-17 | Brc Operations Pty Limited | Method for formulating combination medications for adhd |
US7595310B2 (en) | 2005-09-12 | 2009-09-29 | Solvay Pharmaceuticals, B.V. | Glucuronate salt of a piperazine compound |
US7615551B2 (en) | 2005-09-12 | 2009-11-10 | Solvay Pharmaceuticals, B.V. | Salicylate and gentisate salts of a piperazine compound |
US7709024B2 (en) | 2005-09-12 | 2010-05-04 | Solvay Pharmaceuticals B.V. | Sustained-release formulation and uses thereof |
US8318785B2 (en) | 2005-07-18 | 2012-11-27 | Orion Corporation | Pharmaceutical compounds |
WO2013014274A1 (en) | 2011-07-28 | 2013-01-31 | Ge Healthcare Limited | 5ht1a antagonist useful for in vivo imaging |
US9089567B2 (en) | 2001-01-29 | 2015-07-28 | Otsuka Pharmaceutical Co., Ltd. | Method of treating cognitive impairments and schizophrenias |
US9359302B2 (en) | 2001-09-25 | 2016-06-07 | Otsuka Pharmaceutical Co., Ltd. | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
US10174011B2 (en) | 2014-03-07 | 2019-01-08 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Heterocyclic compounds, process for preparation of the same and use thereof |
US11426366B2 (en) | 2015-05-15 | 2022-08-30 | Arizona Board Of Regents On Behalf Of The Universsity Of Arizona | Compositions and methods for treating motor disorders |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HN1999000146A (en) * | 1998-09-21 | 2000-11-11 | Pfizer Prod Inc | PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PARKINSON'S DISEASE, ADHD AND MICROADENOMAS. |
ES2425114T3 (en) * | 2000-03-16 | 2013-10-11 | The Mclean Hospital Corporation | CDP-choline and uridine for the treatment of alcohol abuse |
US20030036555A1 (en) * | 2001-08-03 | 2003-02-20 | Boehringer Ingelheim Pharma Kg | Pramipexole for the treatment of ADHD |
US7737128B2 (en) * | 2004-06-10 | 2010-06-15 | The Mclean Hospital Corporation | Pyrimidines, such as uridine, in treatments for patients with bipolar disorder |
US7947661B2 (en) * | 2004-08-11 | 2011-05-24 | The Mclean Hospital Corporation | Compounds for the treatment of marihuana dependence, withdrawal, and usage |
US9066903B2 (en) * | 2006-02-28 | 2015-06-30 | The United States Of America As Represented By The Department Of Veterans Affairs | Pharmacological treatment of Parkinson's disease |
US20080131492A1 (en) * | 2006-06-23 | 2008-06-05 | Spherics, Inc. | Dosage forms for movement disorder treatment |
CN101318020B (en) * | 2007-06-06 | 2011-09-28 | 四川科瑞德制药有限公司 | Anti-anxiety or/and dumps medicament composition and uses thereof |
US20100041621A1 (en) * | 2008-08-15 | 2010-02-18 | Perry Renshaw | Methods and compositions for improving cognitive performance |
US9463186B2 (en) | 2013-04-15 | 2016-10-11 | Northwestern University | Treatment for dopaminergic disorders |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5281607A (en) * | 1992-10-08 | 1994-01-25 | New York University | Method of using Alpha 2-Antagonists for the Treatment of Neurodegenerative Diseases |
WO1995028933A1 (en) * | 1994-04-23 | 1995-11-02 | Laboratorios Del Dr. Esteve S.A. | Use of arylpiperazine derivatives for the treatment of parkinson's disease and psychosis |
US5616585A (en) * | 1990-06-29 | 1997-04-01 | Pfizer Inc. | Pyridopyrazine derivatives for treating alcohol and nicotine abuse and addiction |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX19222A (en) * | 1989-01-23 | 1993-12-01 | Pfizer | ANSIOLYTIC AGENTS BIS-AZA-BICYCLIC |
DK0765320T3 (en) * | 1994-06-14 | 2001-11-26 | Pfizer | Benzimidazolone derivatives with central dopaminergic activity |
US5877183A (en) * | 1996-06-06 | 1999-03-02 | Ergo Research Corporation | Treatment of lipid and glucose metabolism disorders with dopamine and serotonin agonists |
HN1999000146A (en) * | 1998-09-21 | 2000-11-11 | Pfizer Prod Inc | PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PARKINSON'S DISEASE, ADHD AND MICROADENOMAS. |
-
1999
- 1999-08-27 HN HN1999000146A patent/HN1999000146A/en unknown
- 1999-09-03 KR KR10-2003-7014169A patent/KR20030088512A/en not_active Application Discontinuation
- 1999-09-03 KR KR10-2004-7006381A patent/KR20040054752A/en not_active Application Discontinuation
- 1999-09-03 SK SK359-2001A patent/SK3592001A3/en unknown
- 1999-09-03 YU YU21701A patent/YU21701A/en unknown
- 1999-09-03 EP EP99939567A patent/EP1115402A1/en not_active Withdrawn
- 1999-09-03 IL IL14150799A patent/IL141507A0/en unknown
- 1999-09-03 GE GEAP19995812A patent/GEP20033081B/en unknown
- 1999-09-03 CZ CZ20011006A patent/CZ20011006A3/en unknown
- 1999-09-03 CA CA002344670A patent/CA2344670A1/en not_active Abandoned
- 1999-09-03 NZ NZ509855A patent/NZ509855A/en unknown
- 1999-09-03 KR KR10-2001-7003552A patent/KR100468340B1/en not_active IP Right Cessation
- 1999-09-03 ID IDW20010637A patent/ID28028A/en unknown
- 1999-09-03 TR TR2004/02083T patent/TR200402083T2/en unknown
- 1999-09-03 HU HU0103691A patent/HUP0103691A3/en unknown
- 1999-09-03 WO PCT/IB1999/001503 patent/WO2000016777A1/en not_active Application Discontinuation
- 1999-09-03 EE EEP200100179A patent/EE200100179A/en unknown
- 1999-09-03 IL IL16483999A patent/IL164839A0/en unknown
- 1999-09-03 AP APAP/P/2001/002102A patent/AP1456A/en active
- 1999-09-03 TR TR2001/01357T patent/TR200101357T2/en unknown
- 1999-09-03 BR BR9913975-8A patent/BR9913975A/en not_active IP Right Cessation
- 1999-09-03 JP JP2000573738A patent/JP2002526448A/en active Pending
- 1999-09-03 OA OA1200100068A patent/OA11653A/en unknown
- 1999-09-03 CN CN99811132A patent/CN1319013A/en active Pending
- 1999-09-03 EA EA200301063A patent/EA200301063A1/en unknown
- 1999-09-03 AU AU53831/99A patent/AU760230B2/en not_active Ceased
- 1999-09-03 EA EA200100204A patent/EA200100204A1/en unknown
- 1999-09-03 PL PL99346904A patent/PL346904A1/en unknown
- 1999-09-13 GT GT199900154A patent/GT199900154A/en unknown
- 1999-09-15 PA PA19998482001A patent/PA8482001A1/en unknown
- 1999-09-15 TW TW088115941A patent/TW518225B/en not_active IP Right Cessation
- 1999-09-17 MY MYPI99004051A patent/MY127939A/en unknown
- 1999-09-17 AR ARP990104680A patent/AR029739A1/en unknown
- 1999-09-17 PE PE1999000948A patent/PE20001084A1/en not_active Application Discontinuation
- 1999-09-20 MA MA25774A patent/MA26690A1/en unknown
- 1999-09-20 DZ DZ990194A patent/DZ2894A1/en active
- 1999-09-20 TN TNTNSN99177A patent/TNSN99177A1/en unknown
- 1999-09-21 US US09/400,659 patent/US6300329B1/en not_active Expired - Fee Related
- 1999-09-21 CO CO99059863A patent/CO5140075A1/en unknown
-
2001
- 2001-02-20 IS IS5852A patent/IS5852A/en unknown
- 2001-03-20 NO NO20011409A patent/NO20011409L/en not_active Application Discontinuation
- 2001-03-20 HR HR20010209A patent/HRP20010209A2/en not_active Application Discontinuation
- 2001-04-13 BG BG105445A patent/BG105445A/en unknown
- 2001-05-03 US US09/848,068 patent/US6608064B2/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5616585A (en) * | 1990-06-29 | 1997-04-01 | Pfizer Inc. | Pyridopyrazine derivatives for treating alcohol and nicotine abuse and addiction |
US5281607A (en) * | 1992-10-08 | 1994-01-25 | New York University | Method of using Alpha 2-Antagonists for the Treatment of Neurodegenerative Diseases |
US5281607B1 (en) * | 1992-10-08 | 1998-05-19 | Univ New York | Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases |
WO1995028933A1 (en) * | 1994-04-23 | 1995-11-02 | Laboratorios Del Dr. Esteve S.A. | Use of arylpiperazine derivatives for the treatment of parkinson's disease and psychosis |
Non-Patent Citations (3)
Title |
---|
JACKSON D.M. ET AL.: "Time course of bromocriptine induced excitation in the rat: behavioural and biochemical studies.", NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, vol. 351, no. 2, 1995, pages 146 - 155, XP002122877 * |
PRAKASH, C. ET AL.: "Metabolism and excretion of a new anxiolytic drug candidate, CP-93,393, in healthy male volunteers", DRUG METABOLISM AND DISPOSITION, vol. 26, no. 5, 1998, pages 448 - 456, XP002122878 * |
See also references of EP1115402A1 * |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002036107A3 (en) * | 2000-11-03 | 2003-01-16 | Univ Manchester | Treatment of motor fluctuations with 5-hydroxytryptamine 1a receptor activity enhancing coumpounds |
WO2002036107A2 (en) * | 2000-11-03 | 2002-05-10 | Motac Neuroscience Limited | Treatment of motor fluctuations with 5-hydroxytryptamine 1a receptor activity enhancing coumpounds |
US9668995B2 (en) | 2000-11-03 | 2017-06-06 | Motac Neuroscience Limited | Treatment of motor fluctuations |
US9387207B2 (en) | 2001-01-29 | 2016-07-12 | Otsuka Pharmaceutical Co., Ltd. | 5-HT1A receptor subtype agonist |
US9089567B2 (en) | 2001-01-29 | 2015-07-28 | Otsuka Pharmaceutical Co., Ltd. | Method of treating cognitive impairments and schizophrenias |
WO2002102988A2 (en) * | 2001-06-18 | 2002-12-27 | Psychiatric Genomics, Inc. | Method for neural stem cell differentiation using 5ht-1a agonists |
WO2002102988A3 (en) * | 2001-06-18 | 2003-02-27 | Psychiatric Genomics Inc | Method for neural stem cell differentiation using 5ht-1a agonists |
US7132287B2 (en) | 2001-06-18 | 2006-11-07 | Psychiatric Genomics, Inc. | Method for neural stem cell differentiation using 5HT-1A agonists |
US10150735B2 (en) | 2001-09-25 | 2018-12-11 | Otsuka Pharmaceutical Co., Ltd. | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
US9359302B2 (en) | 2001-09-25 | 2016-06-07 | Otsuka Pharmaceutical Co., Ltd. | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
US8318785B2 (en) | 2005-07-18 | 2012-11-27 | Orion Corporation | Pharmaceutical compounds |
US7709024B2 (en) | 2005-09-12 | 2010-05-04 | Solvay Pharmaceuticals B.V. | Sustained-release formulation and uses thereof |
US7615551B2 (en) | 2005-09-12 | 2009-11-10 | Solvay Pharmaceuticals, B.V. | Salicylate and gentisate salts of a piperazine compound |
US7595310B2 (en) | 2005-09-12 | 2009-09-29 | Solvay Pharmaceuticals, B.V. | Glucuronate salt of a piperazine compound |
WO2008083442A1 (en) * | 2007-01-10 | 2008-07-17 | Brc Operations Pty Limited | Method for formulating combination medications for adhd |
WO2013014274A1 (en) | 2011-07-28 | 2013-01-31 | Ge Healthcare Limited | 5ht1a antagonist useful for in vivo imaging |
US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
EP3610890A1 (en) | 2012-11-14 | 2020-02-19 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
US10624875B2 (en) | 2012-11-14 | 2020-04-21 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
US10174011B2 (en) | 2014-03-07 | 2019-01-08 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Heterocyclic compounds, process for preparation of the same and use thereof |
US11426366B2 (en) | 2015-05-15 | 2022-08-30 | Arizona Board Of Regents On Behalf Of The Universsity Of Arizona | Compositions and methods for treating motor disorders |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6608064B2 (en) | Pharmaceutical agents for the treatment of Parkinson's disease, ADHD and microadenomas | |
US20040220184A1 (en) | Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD) | |
Baumeister et al. | Historical development of the dopamine hypothesis of schizophrenia | |
Langer et al. | Reduced growth hormone responses to amphetamine in endogenous depressive patients: Studies in normal, reactive and endogenous depressive, schizophrenic, and chronic alcoholic subjects | |
Rothman et al. | Therapeutic and adverse actions of serotonin transporter substrates | |
Bonhomme et al. | Evidence for 5-HT4 receptor subtype involvement in the enhancement of striatal dopamine release induced by serotonin: a microdialysis study in the halothane-anesthetized rat | |
Baumann et al. | Effects of phentermine and fenfluramine on extracellular dopamine and serotonin in rat nucleus accumbens: therapeutic implications | |
van Zwieten | Central imidazoline (I1) receptors as targets of centrally acting antihypertensives: moxonidine and rilmenidine | |
Van Veldhuizen et al. | In vivo microdialysis of noradrenaline overflow: effects of α‐adrenoceptor agonists and antagonists measured by cumulative concentration‐response curves | |
Nisijima et al. | Risperidone counteracts lethality in an animal model of the serotonin syndrome | |
US20070184490A1 (en) | Neuronal nicotinic receptor ligands and their use | |
US20050038015A1 (en) | Partial dopamine-D 2 receptor agonist plus serotonin and/oder noradrenaline inhibitor activity | |
Osman et al. | Idazoxan: a selective α2-antagonist and effective sustained antidepressant in two bipolar depressed patients | |
Yakubu-Madus et al. | Metabolic and hemodynamic effects of moxonidine in the Zucker diabetic fatty rat model of type 2 diabetes. | |
CA2093009A1 (en) | Use of antagonists or partial agonists on the 5-ht 1a receptor for the treatment and prevention of cognitive disorders | |
US5824680A (en) | Ipsapirone for the treatment of alzheimer's disease by improving memory | |
Kuczenski et al. | Dynamic changes in sensitivity occur during the acute response to cocaine and methylphenidate | |
MXPA01002946A (en) | Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas | |
Estan et al. | Reserpine induces vascular α2‐adrenergic supersensitivity and platelet α2‐adrenoceptor up‐regulation in dog | |
Charlton et al. | Vasoconstrictor and norepinephrine potentiating action of 5-hydroxykynuramine in the isolated perfused rat kidney: involvement of serotonin receptors and alpha 1-adrenoceptors | |
Horiuchi et al. | Do D-1 dopamine receptors mediate dopamine-induced pancreatic exocrine secretion in anesthetized dogs? | |
Roozemond et al. | The effect of orphenadrine and its N-demethyl derivative on the level of 5-hydroxytrypt-amine in rat brain | |
RU2508106C2 (en) | Methods and compositions for treating schizophrenia with using atypical neuroleptic combined therapy | |
Alhaider et al. | Enhancement of imipramine-induced rat brain β-adrenoreceptor desensitization by subacute co-administration of trazodone, zimelidine, quipazine or 5-hydroxytryptophan | |
Smyth et al. | Effects of central and peripheral neuropeptide Y on sodium and water excretion in the rat |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: P-217/01 Country of ref document: YU Ref document number: 99811132.5 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 509855 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 141507 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200100204 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 53831/99 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 20010171 Country of ref document: UZ Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200102029 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3592001 Country of ref document: SK |
|
ENP | Entry into the national phase |
Ref document number: 2000 573738 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999939567 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2344670 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: P20010209A Country of ref document: HR Ref document number: PA/a/2001/002946 Country of ref document: MX Ref document number: 1020017003552 Country of ref document: KR Ref document number: PV2001-1006 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1200100272 Country of ref document: VN |
|
ENP | Entry into the national phase |
Ref document number: 1999 105445 Country of ref document: BG Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001/01357 Country of ref document: TR |
|
WWP | Wipo information: published in national office |
Ref document number: 1999939567 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1020017003552 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: PV2001-1006 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 53831/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1200300883 Country of ref document: VN |
|
WWR | Wipo information: refused in national office |
Ref document number: 1020017003552 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004/02083 Country of ref document: TR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 164839 Country of ref document: IL |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999939567 Country of ref document: EP |